Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Br J Cancer
; 121(3): 281, 2019 Jul.
Article
in En
| MEDLINE
| ID: mdl-31123346
ABSTRACT
The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the followingM.C.H. has the following competing interests to declare Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare.The authors apologise for any convenience this may have caused.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Br J Cancer
Year:
2019
Document type:
Article
Affiliation country:
United States